Investigation of the inhibitory effects of simvastatin in RPMI 2650: An in-vitro study

Authors

  • KH Jaapar Centre of Preclinical Science Studies, Faculty of Dentistry, Universiti Teknologi MARA Sungai Buloh Campus, Jalan Hospital, 47000 Sungai Buloh, Selangor, Malaysia
  • ZN Zuhairi Centre of Preclinical Science Studies, Faculty of Dentistry, Universiti Teknologi MARA Sungai Buloh Campus, Jalan Hospital, 47000 Sungai Buloh, Selangor, Malaysia
  • NA Sani Gapor Centre of Preclinical Science Studies, Faculty of Dentistry, Universiti Teknologi MARA Sungai Buloh Campus, Jalan Hospital, 47000 Sungai Buloh, Selangor, Malaysia
  • NA Bismelah Centre of Preclinical Science Studies, Faculty of Dentistry, Universiti Teknologi MARA Sungai Buloh Campus, Jalan Hospital, 47000 Sungai Buloh, Selangor, Malaysia
  • NAH Mohamed Centre of Preclinical Science Studies, Faculty of Dentistry, Universiti Teknologi MARA Sungai Buloh Campus, Jalan Hospital, 47000 Sungai Buloh, Selangor, Malaysia

DOI:

https://doi.org/10.24191/cos.v9i1.16788

Keywords:

anticancer, simvastatin, human squamous nasal cell carcinoma, head and neck carcinoma

Abstract

Objective: The present study was carried out to investigate the antiproliferative effects of simvastatin involving Human Squamous Nasal Cell Carcinoma (RPMI 2650 cell line), which is one of the most common head and neck cancers with the highest incidence and mortality rates in Asian countries. The anti-cancer effects of simvastatin in NPC have not yet been investigated in depth, hence it will be illustrated in the present study. Materials and methods: The cells were treated with various concentrations of Simvastatin in a dose dependent (0, 0.1, 0. 4, 3.0 mg/ml) and time dependent (24, 48 and 72 hours) manner. The cancer cell viability was then assessed by using MTT assay at absorbance of 590 nm. Results: Simvastatin induced reduction in cell viability number and induced apoptosis in RPMI 2650 cell line. Simvastatin for 72 h significantly reduced cell growth as compared to 48 and 24 h pre-incubation with simvastatin treatment. After 72 h incubation with 0.1 mg/ml, 0.4 mg/ml and 3.0 mg/ml simvastatin, the cell viability decreased from 100% in treated control cells to 23%, 21% and 14% respectively. Conclusions: This finding demonstrate the potential of simvastatin and probably may have therapeutic benefit for NPC cell growth.

Downloads

Published

2022-03-01

How to Cite

Jaapar, K., Zuhairi, Z., Sani Gapor, N., Bismelah, N., & Mohamed, N. (2022). Investigation of the inhibitory effects of simvastatin in RPMI 2650: An in-vitro study. Compendium of Oral Science, 9(1), 1–7. https://doi.org/10.24191/cos.v9i1.16788

Issue

Vol. 9 No. 1 (2022): Compendium of Oral Science

Section

Original Article

License

Copyright (c) 2024 Compendium of Oral Science

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Materials contained in the journal may be reproduced for educational purposes provided that both the author(s) and the journal are appropriately recognised; otherwise duplication is not permitted. No articles, reports, or portions there of may be translated into other languages, published in books, journals, magazines, or any other print form without written permission from the authors and from the journal.

Disclaimer: The statements, opinions and data expressed in the articles and reports herein are those of the author(s) and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any schemes, methods, instructions or ideas referred to in the content.